DUSA PHARMACEUTICLS (NASDAQ:DUSA)
1.60
0.02 (1.23%)
| DUSA PHARMACEUTICLS (NASDAQ:DUSA) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $1.62 | 52 Week High | $1.80 | ||
| Open | $1.59 | 52 Week Low | $0.88 | ||
| Day High | $1.70 | P/E | N/A | ||
| Day Low | $1.59 | EPS | $-0.21 | ||
| Volume | 26,975 | ||||
| More DUSA Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| AER | 1 | MCCC | 1 |
| DM | 1 | RAIL | 1 |
| HH | 1 | AIG | 1 |
| MDCI | 1 | EIX | 1 |
| REIS | 1 | INHX | 1 |
| AYR | 1 | MIR | 1 |
Entities who have mentioned DUSA
- Merriman Curhan Ford | View Related Stories »
- Rodman & Renshaw | View Related Stories »
- Nonfarm Payrolls | View Related Stories »
- Trading Radar | View Related Stories »
StreetInsider.com Major News for DUSA
View All ReportsStreetInsider.com Reports on DUSA
- DUSA Pharma (DUSA) Encouraged By SCC Study to Explore Benefits of Levulan PDT
- DUSA Pharma (DUSA) Posts Q3 Loss of 2c, Beats by 2c
- Trading Radar for 11/06: American International (AIG), Scripps (SNI), Suncor Energy (SU), Blackstone Group (BX) Report
View All Press ReleasesCompany Press Releases on DUSA
- Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent Reduction in New Squamous Cell Carcinoma Lesions in Solid Organ Transplant Recipients Over a 2-Year Period
- DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
- DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results
- DUSA Pharmaceuticals, Inc.(R) Announces Third Quarter Financial Results and Corporate Highlights Conference Call
- DUSA Pharmaceuticals Named to Deloitte's 2009 Technology Fast 500 List of Fastest Growing Companies in North America
StreetInsider Reports on DUSA by Category
Comments on DUSA
No comments are currently available.
